Anika Therapeutics (STU:AKP) Asset Turnover: 0.16 (As of Mar. 2026)


STU:AKP Anika Therapeutics Inc STU:AKP
63 GF Score
Price €13.80
GF Value €17.89
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Asset Turnover?

Anika Therapeutics STU:AKP 63 Asset Turnover is 0.16 as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 63/100 and a GF Value™ of €17.89 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Anika Therapeutics's Revenue for the three months ended in Mar. 2026 was €25.61 Mil. Anika Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was €158.83 Mil. Therefore, Anika Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.16.

Asset Turnover is linked to ROE % through Du Pont Formula. Anika Therapeutics's annualized ROE % for the quarter that ended in Mar. 2026 was -14.68%. It is also linked to ROA % through Du Pont Formula. Anika Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -11.01%.

Anika Therapeutics  (STU:AKP) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Anika Therapeutics's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-17.492/119.1715
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-17.492 / 102.456)*(102.456 / 158.8305)*(158.8305/ 119.1715)
=Net Margin %*Asset Turnover*Equity Multiplier
=-17.07 %*0.6451*1.3328
=ROA %*Equity Multiplier
=-11.01 %*1.3328
=-14.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Anika Therapeutics's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-17.492/158.8305
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-17.492 / 102.456)*(102.456 / 158.8305)
=Net Margin %*Asset Turnover
=-17.07 %*0.6451
=-11.01 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Anika Therapeutics Asset Turnover Related Terms

Anika Therapeutics Asset Turnover Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Asset Turnover Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.34 0.38 0.52 0.54

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.14 0.15 0.16 0.16

STU:AKP vs LFCR, DERM, ASRT: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anika Therapeutics Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Asset Turnover falls into.


STU:AKP
63GF Score
Anika Therapeutics Inc STU:AKP
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Anika Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=96.347/( (193.617+162.491)/ 2 )
=96.347/178.054
=0.54

Anika Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=25.614/( (162.491+155.17)/ 2 )
=25.614/158.8305
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.16 mean?
Anika Therapeutics (STU:AKP) has a Asset Turnover of 0.16 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Asset Turnover too high?
Anika Therapeutics' current Asset Turnover is 0.16. Overall, Anika Therapeutics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Asset Turnover compare to LFCR and DERM?
Anika Therapeutics' Asset Turnover of 0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Asset Turnover is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.89, compared to a current price of €13.80 — trading 22.9% below its estimated fair value. The current Asset Turnover is 0.16. Anika Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Asset Turnover is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.80 is trading 22.9% below its estimated GF Value™ of €17.89. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • Asset Turnover: 0.16
  • GF Value™: €17.89 vs. price of €13.80 (22.9% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
63GF Score

Get the complete analysis for STU:AKP

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.80
Price
€17.89
GF Value